Madrigal Pharmaceuticals (MDGL)
(Real Time Quote from BATS)
$285.56 USD
-1.68 (-0.59%)
Updated Jul 22, 2024 11:04 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDGL 285.56 -1.68(-0.59%)
Will MDGL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
2 Top Biotech Buyout Candidates
Other News for MDGL
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Evercore ISI
Madrigal Pharmaceuticals price target raised by $4 at JMP Securities, here's why
Madrigal Pharmaceuticals initiated with neutral view at Cantor Fitzgerald
Madrigal Pharmaceuticals Enhances Stock Plan and Re-elects Board
GLP-1 drugs linked to reduced dementia risk: study